Evidence map›Paper›PMID 37735165›Full record

ArticleNPJ systems biology and applications2023

Experiment-based computational model predicts that IL-6 classic and trans-signaling exhibit similar potency in inducing downstream signaling in endothelial cells.

Min Song, Youli Wang, Brian H Annex, Aleksander S Popel

Open access · goldAbstract read
In one paragraph

Article in NPJ systems biology and applications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.3field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Supercritical COMaterials today. Bio · 2026
    Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Min SongDepartment of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA. msong25@jhmi.edu.ORCID http://orcid.org/0000-0002-3901-6304
Youli WangDepartment of Medicine, Augusta University Medical College of Georgia, Augusta, GA, 30912, USA.
Brian H AnnexDepartment of Medicine, Augusta University Medical College of Georgia, Augusta, GA, 30912, USA.ORCID http://orcid.org/0000-0001-6538-8243
Aleksander S PopelDepartment of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, USA.ORCID http://orcid.org/0000-0002-6706-9235
Augusta University · USJohns Hopkins University · US

Funding

Systems Biology of Angiogenesis in Peripheral Arterial DiseaseR01HL101200 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI POPEL, ALEKSANDER S. · 2010 to 2022
$10.7M
Predictive experiment-based multiscale models of the tumor immune microenvironment and immunotherapy in breast cancerR01CA138264 · NCI · JOHNS HOPKINS UNIVERSITY · PI POPEL, ALEKSANDER S. · 2009 to 2023
$8.1M
Precision Medicine for Therapeutic Angiogenesis in Peripheral Arterial Disease: Targeting of the IL21R PathwayR01HL148590 · NHLBI · AUGUSTA UNIVERSITY · PI ANNEX, BRIAN H · 2019 to 2022
$2.9M
The Anti-angiogenic VEGF165b and VEGFR1 Signaling in Peripheral Artery DiseaseR01HL141325 · NHLBI · UNIVERSITY OF VIRGINIA · PI ANNEX, BRIAN H · 2019 to 2022
$2.7M
NCI NIH HHS R01 CA138264NHLBI NIH HHS R01 HL101200NHLBI NIH HHS R01 HL141325NHLBI NIH HHS R01 HL148590
6 · The paper itself

Abstract

Inflammatory cytokine mediated responses are important in the development of many diseases that are associated with angiogenesis. Targeting angiogenesis as a prominent strategy has shown limited effects in many contexts such as cardiovascular diseases and cancer. One potential reason for the unsuccessful outcome is the mutual dependent role between inflammation and angiogenesis. Inflammation-based therapies primarily target inflammatory cytokines such as interleukin-6 (IL-6) in T cells, macrophages, cancer cells, and muscle cells, and there is a limited understanding of how these cytokines act on endothelial cells. Thus, we focus on one of the major inflammatory cytokines, IL-6, mediated intracellular signaling in endothelial cells by developing a detailed computational model. Our model quantitatively characterized the effects of IL-6 classic and trans-signaling in activating the signal transducer and activator of transcription 3 (STAT3), phosphatidylinositol 3-kinase/protein kinase B (PI3K/Akt), and mitogen-activated protein kinase (MAPK) signaling to phosphorylate STAT3, extracellular regulated kinase (ERK) and Akt, respectively. We applied the trained and validated experiment-based computational model to characterize the dynamics of phosphorylated STAT3 (pSTAT3), Akt (pAkt), and ERK (pERK) in response to IL-6 classic and/or trans-signaling. The model predicts that IL-6 classic and trans-signaling induced responses are IL-6 and soluble IL-6 receptor (sIL-6R) dose-dependent. Also, IL-6 classic and trans-signaling showed similar potency in inducing downstream signaling; however, trans-signaling induces stronger downstream responses and plays a dominant role in the overall effects from IL-6 due to the in vitro experimental setting of abundant sIL-6R. In addition, both IL-6 and sIL-6R levels regulate signaling strength. Moreover, our model identifies the influential species and kinetic parameters that specifically modulate the downstream inflammatory and/or angiogenic signals, pSTAT3, pAkt, and pERK responses. Overall, the model predicts the effects of IL-6 classic and/or trans-signaling stimulation quantitatively and provides a framework for analyzing and integrating experimental data. More broadly, this model can be utilized to identify potential targets that influence IL-6 mediated signaling in endothelial cells and to study their effects quantitatively in modulating STAT3, Akt, and ERK activation.

Indexed as

Interleukin-6Proto-Oncogene Proteins c-aktCytokinesEndothelial CellsHumansInflammationPhosphatidylinositol 3-KinasesCytokinesInterleukin-6Phosphatidylinositol 3-KinasesProto-Oncogene Proteins c-akt

Identifiers

PMID37735165
PMCPMC10514195
OpenAlexW4386929166

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.